A revised excitotoxic hypothesis of schizophrenia: Therapeutic implications

Clinical Neuropharmacology

Volumn 24, Issue 1, 2001, Pages 43-49

  Deutsch, Stephen I ^a,b   Rosse, Richard B ^b   Schwartz, Barbara L ^b   Mastropaolo, John ^a  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Excitotoxicity; Glutamate; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID; 6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; DIZOCILPINE; DOPAMINE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; KAINIC ACID RECEPTOR; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE;

ARTICLE; HUMAN; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA;

ANIMALS; DOPAMINE; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HUMANS; NEUROTOXINS; RECEPTORS, GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 0035113905     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200101000-00008     Document Type: Article

References (29)

1. A 'glutamatergic hypothesis' of schizophrenia: Rationale for pharmacotherapy with glycine
2. The glutamatergic dysfunction hypothesis for schizophrenia
3. Schizophrenia and glutamatergic transmission
4. A pivotal role for glutamate in the pathogenesis of schizophrenia, and its cognitive dysfunction
5. The glutamate synapse in neuropsychiatric disorders
6. The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia
7. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains
8. A receptor binding in superficial layers of cingulated cortex in schizophrenics
9. Reduced GABA uptake sites in the temporal lobe in schizophrenia
10. Regionally selective deficits in uptake sites for glutamate and gamma-aminobutyric acid in the basal ganglia in schizophrenia
11. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics
12. 2 subunit mRNAs of the gamma-amino butyrate type A receptor in prefrontal cortex of schizophrenics
13. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs
14. NMDA receptor RNA correlation with antemortem cognitive impairment in schizophrenia
15. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics
16. NR2B-containing NMDA receptors are up-regulated in temporal cortex in schizophrenia
17. Alterations in phencyclidine and sigma binding sites in schizophrenic brains
18. Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: Evidence for glutamate hypothesis
19. Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia
20. Distribution of kainite receptor subunit mRNAs in human hippocampus, neocortex and cerebellum, and bilateral reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia
21. 3H]kainic acid binding in the prefrontal cortex in schizophrenia
22. Dopaminergic and glutamatergic abnormalities in postmortem schizophrenic brain
23. AMPA receptor binding and subunit mRNA expression in prefrontal cortex and striatum of elderly schizophrenics
24. 3H]amino-3-hydroxy-5-methylisoxazole-4-propionic acid binding to human cerebral cortical membranes: Minimal changes in postmortem brains of chronic schizophrenics
25. Glutamate receptors in the postmortem striatum of schizophrenic, suicide, and control brains
26. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex
27. Antipsychotic medication and long-term course of schizophrenia: Therapeutic and theoretical implications
28. Glutamate in schizophrenia: Clinical and research implications
29. Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion